Rachel Jankowitz

7PUBLICATIONS
82CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Immunogenetics (incl. genetic immunology)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Mar 10, 2026
The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease.

Natasha B Hunter, Heather A Parsons, Leslie Cope

|Jul 20, 2024
International survey on invasive lobular breast cancer identifies priority research questions.

Steffi Oesterreich, Leigh Pate, Adrian V Lee

|Jun 27, 2024
Adjuvant Trastuzumab Emtansine Versus Paclitaxel Plus Trastuzumab for Stage I Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: 5-Year Results and Correlative Analyses From ATEMPT.

Paolo Tarantino, Nabihah Tayob, Guillermo Villacampa

|Mar 21, 2024
Reporting on invasive lobular breast cancer in clinical trials: a systematic review.

Karen Van Baelen, Josephine Van Cauwenberge, Marion Maetens

|Feb 17, 2022
Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial.

Romualdo Barroso-Sousa, Paolo Tarantino, Nabihah Tayob

|Jun 02, 2021
Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial.

Sara M Tolaney, Nabihah Tayob, Chau Dang

Pageof 2

Frequent Collaborators

4 joint publications

Rita Nanda

4 joint publications

Mothaffar Rimawi

4 joint publications

Antonio C Wolff

3 joint publications

P Kelly Marcom